What is the recommended approach for assessing, treating, and following up patients with ADHD in primary care, including medication choices (stimulants, atomoxetine, guanfacine, clonidine, bupropion), dosing regimens, monitoring parameters, and follow‑up intervals for children, adolescents, and adults?

ADHD Management and Follow-Up in Primary Care

Stimulant medications (methylphenidate or amphetamines) are the first-line pharmacological treatment for ADHD in both children and adults, with nonstimulants (atomoxetine, guanfacine extended-release, clonidine extended-release) reserved for patients who cannot tolerate stimulants, have inadequate response, or have specific contraindications. 1

Initial Assessment

Before initiating any ADHD medication, obtain:

• Personal and family cardiac history specifically asking about:
  • Sudden death in family members
  • Cardiovascular symptoms
  • Wolff-Parkinson-White syndrome
  • Hypertrophic cardiomyopathy
  • Long QT syndrome
• Screen for bipolar disorder, mania, or hypomania (personal or family history) before starting treatment 2
• If cardiac risk factors are present, obtain ECG and consider cardiology referral before initiating medication 1

Medication Selection Algorithm

First-Line: Stimulants

Stimulants demonstrate superior efficacy for core ADHD symptoms compared to nonstimulants and should be tried first unless contraindicated 1, 3. Both methylphenidate and amphetamine formulations are effective; choice depends on availability and patient factors.

Second-Line: Nonstimulants

Consider nonstimulants when:

• Stimulants cause intolerable side effects
• Inadequate response to stimulants
• Risk of stimulant diversion
• Patient/family preference to avoid stimulants
• Comorbid substance use disorder (atomoxetine preferred) 4, 5

FDA-approved nonstimulants include:

• Atomoxetine
• Guanfacine extended-release
• Clonidine extended-release

Dosing Regimens

Atomoxetine Dosing 2

Children/adolescents ≤70 kg:

• Start: 0.5 mg/kg/day
• Increase after minimum 3 days to target: 1.2 mg/kg/day
• Maximum: 1.4 mg/kg/day or 100 mg (whichever is less)
• Can be given once daily (morning) or divided (morning and late afternoon/evening)

Children/adolescents >70 kg and adults:

• Start: 40 mg/day
• Increase after minimum 3 days to target: 80 mg/day
• After 2-4 additional weeks, may increase to maximum 100 mg if suboptimal response
• Can be given once daily or divided dosing

Special populations:

• Moderate hepatic impairment (Child-Pugh B): Reduce doses to 50% of normal
• Severe hepatic impairment (Child-Pugh C): Reduce doses to 25% of normal
• CYP2D6 poor metabolizers or concurrent strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): Start at lower dose (0.5 mg/kg/day or 40 mg/day), increase to target only after 4 weeks if symptoms persist and initial dose tolerated 2

Guanfacine and Clonidine Extended-Release

Maximum doses vary by country but generally:

• Guanfacine ER: up to 4-6 mg/day 3
• Clonidine ER: up to 0.4 mg/day 3

Critical caveat: These medications must be tapered when discontinuing—never stop abruptly due to risk of rebound hypertension 1

Monitoring Parameters

Cardiovascular Monitoring

For all ADHD medications:

• Baseline heart rate and blood pressure
• Monitor HR and BP at each follow-up visit 1

Expected changes:

• Stimulants: Mild increases (1-2 bpm HR, 1-4 mmHg BP on average), though 5-15% of patients may have more substantial increases 1
• Atomoxetine: May increase HR and BP 1
• Guanfacine/Clonidine ER: May decrease HR and BP 1

Growth Monitoring

• Height and weight at baseline and each visit
• Stimulants may reduce growth velocity by 1-2 cm from predicted adult height, particularly with higher, consistently administered doses; effect diminishes by third year 1
• Atomoxetine may cause growth delays in first 1-2 years with return to expected trajectory after 2-3 years 1

Side Effect Monitoring

Common stimulant side effects:

• Appetite loss
• Abdominal pain
• Headaches
• Sleep disturbance
• Rare: hallucinations/psychotic symptoms 1

Atomoxetine-specific monitoring:

• Initial somnolence and GI symptoms (especially if dose escalated too rapidly)
• Suicidal ideation (FDA black box warning) 1
• Hepatic function if symptoms suggest hepatitis (extremely rare) 1

Guanfacine/Clonidine ER side effects:

• Somnolence, dry mouth, dizziness, irritability, headache, bradycardia, hypotension, abdominal pain 1

Follow-Up Intervals

Initial Titration Phase

• Follow-up every 1-2 weeks during dose titration to assess:
  • Symptom improvement
  • Side effects
  • Vital signs
  • Growth parameters

Maintenance Phase

• Once stable dose achieved, follow-up every 3-6 months 2
• Periodically reevaluate long-term need for medication 2
• Pharmacological treatment may be needed for extended periods; maintenance treatment has demonstrated benefit in controlled trials 2

Adjunctive Therapy

If stimulant monotherapy is partially effective or limited by side effects:

• Guanfacine ER or clonidine ER are FDA-approved for adjunctive use with stimulants 1
• Atomoxetine has limited evidence supporting combination with stimulants (off-label) 1

Key Clinical Pitfalls to Avoid

1. Never abruptly discontinue guanfacine or clonidine—always taper to prevent rebound hypertension 1
2. Do not open atomoxetine capsules—must be swallowed whole 2
3. Do not exceed maximum doses: Atomoxetine 100 mg/day in adults; safety of doses >150 mg/day not established 2
4. Screen for bipolar disorder before initiating any ADHD medication to avoid precipitating mania 2
5. Adjust atomoxetine dosing in hepatic impairment and with CYP2D6 inhibitors 2
6. Atomoxetine can be discontinued without tapering, unlike alpha-agonists 2

Comprehensive Treatment Approach

ADHD medication should be part of a comprehensive treatment program that may include psychological, educational, and social interventions 2. However, medication is not indicated for symptoms secondary to environmental factors or other primary psychiatric disorders including psychosis 2.